Search

Your search keyword '"Gagnard JC"' showing total 3 results
Start Over Author "Gagnard JC" Publication Year Range Last 10 years
3 results on '"Gagnard JC"'

3. Enterocytozoon bieneusi Microsporidiosis in Stem Cell Transplant Recipients Treated with Fumagillin

Author

Bukreyeva I, Angoulvant A, Bendib I, Gagnard JC, Bourhis JH, Dargère S, Bonhomme J, Thellier M, Gachot B, and Wyplosz B

Subjects
Adult, Antifungal Agents adverse effects, Cyclohexanes adverse effects, Enterocytozoon pathogenicity, Enterocytozoon physiology, Fatty Acids, Unsaturated adverse effects, Female, Humans, Immunosuppressive Agents therapeutic use, Leukemia, Myeloid pathology, Leukemia, Myeloid therapy, Male, Microsporidiosis diagnosis, Microsporidiosis microbiology, Middle Aged, Mycophenolic Acid therapeutic use, Platelet Count, Prednisone therapeutic use, Sesquiterpenes administration & dosage, Sesquiterpenes adverse effects, Thrombocytopenia chemically induced, Treatment Outcome, Antifungal Agents administration & dosage, Cyclohexanes administration & dosage, Enterocytozoon drug effects, Fatty Acids, Unsaturated administration & dosage, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid immunology, Microsporidiosis drug therapy
Abstract

Enterocytozoon bieneusi microsporidiosis is an emerging disease in immunocompromised patients. We report 2 cases of this disease in allogeneic hematopoietic stem cell transplant patients successfully treated with fumagillin. Thrombocytopenia occurred but without major adverse events. Modifications of immunosuppression could be avoided when E. bieneusi is rapidly identified and fumagillin therapy is started promptly.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results